The National Lung Cancer Audit (NLCA) is running a spotlight audit evaluating molecular testing in patients diagnosed with advanced non-small cell lung cancer (NSCLC) in mid-October. RCP research fellow Judith Tweedie explains why.
The NLCA team plans to launch a spotlight audit evaluating the frequency and efficacy of molecular testing in eligible patients with advanced NSCLC. Preparation for the audit has taken place in collaboration with our colleagues at Public Health England and the University of Nottingham.
The spotlight will aim to;
The spotlight audit has proven to be an essential new workstream for the NLCA. Our previous spotlight audit of early-stage disease not treated with surgery provided major insights into the management of these patients. As molecular testing plays a critical role in the treatment of advanced lung cancer, to ensure the best care, it is imperative that we understand its current position in the diagnosis of NSCLC in order to support trusts and individuals to provide the highest standards of care.
As part of the project we have also created a portal that will streamline the process for participant’s data entry, which has been piloted by members of the NLCA user’s group. This year we are delighted to report that trusts will receive individualised reports providing a summary of their results.
The report will also include an overview of the nationalised data which trusts can use to benchmark their performance.
Like our previous spotlight audit, we will be asking every trust in England which contributes to the NLCA to also submit to this spotlight audit. All participants will require an NHS email to register with the portal. As registration may take a few working days, trusts are urged to register as soon as possible. In addition to the trusts’ reports, the data will be published in a peer-reviewed journal and included in the annual report.
National and international guidelines have recommended the inclusion of molecular testing for mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene re-arrangements since 2013 (Lindeman et al., 2013; NICE, 2013). Identification of these mutations/translocations is essential in determining the correct choice of tyrosine kinase inhibitor (TKI) in advanced NSCLC.
Increasingly, recommendations for molecular testing have also included the quantification of tumour PD-L1 expression. Monoclonal antibody therapies can target the PD receptor and ligand, reducing the capabilities of a tumour to evade the immune system thus providing a further therapeutic option (Cree et al., 2016). NICE approved nivolumab and pembrolizumab) in 2017 but both agents require positive molecular testing for PD-L1 as a prerequisite for use.
While the necessity for expanding molecular testing in advanced NSCLC is evident, widespread implementation of recommendations can be challenging. Previous studies have suggested that the frequency of molecular testing for patients with advanced NSCLC has been estimated to be in the region of 16%-38% (Ellis et al., 2011; Enewold and Thomas, 2016; McKeage et al., 2017; Shen et al., 2017). Common difficulties citied included inadequate biopsy sampling, lack of awareness, difficulties with funding, lack of appropriate laboratory infrastructure, remote geography and co-morbidity and age of the patient (Cree et al., 2016; Enewold and Thomas, 2016; Lim et al., 2017; Shen et al., 2017).
Dr Jude Tweedie is an RCP research fellow. You can follow her on twitter at @JudeTweedie.